Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $62 to $66.
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $62 to $66.
